Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03431077 · ClinicalTrials.gov registry record · Phase 2
A Study of LJPC-501 in Pediatric Patients With Hypotension
A Phase 2 study, sponsored by La Jolla Pharmaceutical Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT03431077: Completed Phase 2 study, sponsored by La Jolla Pharmaceutical Company.
NCT03431077 is a Phase 2 study that has completed, run by La Jolla Pharmaceutical Company. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03431077, a Phase 2 study, has completed, sponsored by La Jolla Pharmaceutical Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the effect of LJPC-501 infusion on mean arterial pressure (MAP) or reduction in sum norepinephrine (NE) equivalent dosing, at Hour 2 after the start of LJPC-501, in pediatric patients who remain hypotensive despite receiving fluid therapy and vasopressor therapy. In addition, this study will evaluate the safety and tolerability of LJPC-501 in pediatric patients, the change in MAP over 24 hours after the start of LJPC-501, the change in serum lactate concentrations, and the change in Pediatric Logistic Organ Dysfunction (PELOD) scores.
Primary Outcome
To evaluate the effect of LJPC-501 infusion on mean arterial pressure (MAP).
Interventions
- DRUG Angiotensin II
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2018-02-11 |
| Est. Completion | 2018-04-14 |
| Phase | Phase 2 |
What the finished NCT03431077 record still lists
NCT03431077 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Angiotensin II is the first listed.
NCT03431077 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03431077 about?
NCT03431077 is a clinical study titled "A Study of LJPC-501 in Pediatric Patients With Hypotension". The objective of this study is to evaluate the effect of LJPC-501 infusion on mean arterial pressure (MAP) or reduction in sum norepinephrine (NE) equivalent dosing, at Hour 2 after the start of LJPC-501, in pediatric patients who remain hypotensive despite receiving fluid therapy and vasopressor th...
What is the current status of trial NCT03431077?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2018-02-11. Estimated completion is 2018-04-14.
What interventions are being tested in trial NCT03431077?
The interventions under investigation include: Angiotensin II (DRUG).
Who is sponsoring clinical trial NCT03431077?
This trial is sponsored by La Jolla Pharmaceutical Company, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03431077's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI